Hepatect

Hepatect is a prescription immunoglobulin product whose active ingredient is human hepatitis B immunoglobulin, supplied as an injectable solution for intravenous administration. It is manufactured for the European market and classified as an antiviral immunoprophylaxis agent. Hepatect provides passive immunity by delivering anti‑HBs antibodies that can neutralize hepatitis B virus, helping to prevent infection or recurrence in specific clinical situations under established clinical guidelines and recommendations.

Hepatect is indicated for specific situations where passive immunity against hepatitis B virus is required.

- Post‑exposure prophylaxis for individuals who have been exposed to hepatitis B virus and are not adequately protected by vaccination. - Prevention of hepatitis B virus recurrence in patients undergoing orthotopic liver transplantation. - Supplementation of anti‑HBs antibodies in patients with chronic liver disease who have low endogenous antibody levels. - Use in immunocompromised patients who cannot mount an adequate response to hepatitis B vaccination. - Administration to newborns of hepatitis B‑positive mothers when active immunization is delayed.

The safety profile of Hepatect reflects the typical reactions observed with human immunoglobulin preparations administered intravenously.

Common: - Mild fever, chills, or rigors that develop within minutes to a few hours after the infusion. - Headache, dizziness, or a sensation of light‑headedness during or shortly after the injection. - Nausea, vomiting, abdominal cramping, or loss of appetite occurring in the first 24 hours. - Localized pain, redness, swelling, or a small bruise at the site where the intravenous line was placed. - Transient low blood pressure or rapid heart rate observed during the infusion.

Serious: - Severe allergic reactions including anaphylaxis, angioedema, or widespread urticaria requiring emergency treatment. - Acute hemolytic transfusion reaction manifested by hemoglobinuria, back pain, or sudden drop in hemoglobin levels. - Renal dysfunction such as acute kidney injury or worsening of pre‑existing renal disease.

When prescribing or administering Hepatect, clinicians should consider several precautionary measures to ensure safe use.

- Assess patient’s history for prior reactions to blood products or immunoglobulin therapy. - Verify hepatitis B surface antigen and antibody status before use to avoid unnecessary treatment. - Monitor vital signs and for signs of hypersensitivity during the infusion and for at least 30 minutes afterward. - Adjust dosage or infusion rate in patients with renal impairment or fluid overload risk. - Avoid use in individuals with known severe IgA deficiency unless IgA‑deficient preparations are available. - Consider pregnancy status; the safety profile in pregnant women has not been established. - Ensure appropriate storage and handling of the product according to manufacturer guidelines.

Hepatect may interact with other medications or clinical conditions; awareness of these interactions helps to minimize adverse outcomes.

Avoid: - Concurrent administration of other human immunoglobulin products, which can increase the risk of hyperviscosity. - Live viral vaccines given within 4 weeks of Hepatect infusion, as passive antibodies may diminish vaccine efficacy.

Use with caution: - Anticoagulants or antiplatelet agents, because infusion‑related vascular reactions can exacerbate bleeding risk. - Immunosuppressive agents, which may alter the patient’s response to passive immunization. - Renal‑clearing drugs (e.g., aminoglycosides, contrast media) in patients with compromised kidney function, due to potential additive nephrotoxicity.